ClinicalTrials.gg
Not yet recruitingNCT07938151Updated Nov 16, 2026

Timeliness, Parental Acceptability, and Safety of Same-Day Administration of Varicella and Hepatitis A Vaccines Among Children: An Observational Study

An observational study in Hepatitis A Vaccine and Varicella Immunisation, sponsored by Shandong University. Not yet recruiting at 1 site in China. Open to participants aged 12 Months to 23 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Shandong University · Observational

Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
35,000
Ages
12 Months to 23 Months
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 25 studies in Hepatitis with a site in China — 6 open to participants now, 7 under way, none of them phase 3. Hepatitis · China.

Started
2026
with 1 other
Observational
9 of 25
4 open now
Registered
25th of 25
by date

Among the 25 studies in Hepatitis with a site in China, this one is one of 2 that started in 2026, is one of 9 observational ones, and was the 25th registered.

Hepatitis

343 studies on the registry are indexed under Hepatitis; 51 are open to participants now.

Browse Hepatitis studies →

Open to participants now

6 of the 25 studies in Hepatitis with a site in China are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 36 Hepatitis studies recruiting now, 23 (64%) set no upper age limit and 11 (31%) stop at 75 or younger; 6 take children under 18; 8 take healthy volunteers.

This study: 12 Months to 23 Months · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies in Hepatitis with a site in China, or all of them as a file.
02

Study summary

The goal of this observational study is to learn whether offering same-day co-administration of the varicella (chickenpox) vaccine and the inactivated hepatitis A vaccine at routine vaccination clinics helps children in China complete both vaccines on time, and how parents feel about this service.

The main questions it aims to answer are:

  • Do parents accept same-day administration of the two vaccines when clinics offer this option?
  • Are children more likely to complete both vaccines within 90 days when the same-day option is available?

Participants will receive routine vaccination care as usual. After clinic staff explain the options - both vaccines on the same day at different injection sites, on different days, or waiting - parents freely choose, and the study records the choice. Families who take part receive short follow-up contacts about 1 week, 1 month, and 6 weeks after each vaccination to ask about fever, rash, or other health problems, complete a short satisfaction survey at 1 month, and are followed for 90 days through immunization records. Results will also be compared with de-identified immunization records of similar children from the same clinics before the service was introduced.

03

Conditions studied

  • Hepatitis A Vaccine
  • Varicella Immunisation

Browse trials for

Keywords

  • Vaccine Co-Administration
  • Vaccination Timeliness
  • Parental Acceptance
04

Who can participate

Ages eligible
12 Months to 23 Months
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Children aged 12-23 months attending participating primary-level vaccination clinics in Shandong Province, China, who are due for the first dose of a live attenuated varicella vaccine and/or indicated doses of inactivated hepatitis A vaccine. Screening is consecutive on each vaccination day.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 12-23 months at screening.
  • The immunization information system shows that the first dose of varicella vaccine and/or the indicated dose of inactivated hepatitis A vaccine is still due.
  • Passes the clinician's health inquiry, screening and vaccination suitability assessment on the enrollment day.
  • The guardian understands the study and signs written .
  • The guardian is willing to accept study follow-up and can be contacted in person or by telephone for medical information verification.

Exclusion criteria

Exclusion Criteria:

  • Has already completed the doses of varicella vaccine and hepatitis A vaccine required for the study observations before screening.
  • Previous severe allergic reaction to any component of the vaccines to be administered.
  • Has a clear vaccination listed in the package inserts or national guidelines making inclusion in the study observations unsuitable.
  • Recent use of immunoglobulin, blood products or therapy affecting scheduling, with no possibility of completing follow-up assessments within the observation windows.
  • The guardian is unable to complete follow-up or refuses to provide necessary study information.

Children with temporary health conditions leading to deferral on that day may enter the Deferred/Unvaccinated Group for acceptance, service process and timeliness observations, but are not included in the post-vaccination safety analysis of that episode.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
35,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • Same-Day Co-Administration Group

    Children aged 12-23 months who, on the day of enrollment, are assessed by the vaccination clinician as eligible for both the first dose of a live attenuated varicella vaccine and an inactivated hepatitis A vaccine , and whose guardians voluntarily choose to receive both vaccines on the same calendar day at different injection sites. Children receive routine care including a 30-minute on-site observation period after vaccination, followed by active safety follow-up on Days 7 (+/-2), 30 (+/-5) and 42 (+/-7). Parental satisfaction is assessed at Day 30, and vaccination timeliness (completion of both vaccines, number of visits, reasons for delay) is tracked through Day 90 after screening. Co-administration of other age-appropriate vaccines (e.g., MMR, DTaP) is permitted and recorded; these children are analyzed as a prespecified subgroup.

    Biological: Live Attenuated Varicella Vaccine · Biological: Inactivated Hepatitis A Vaccine

  • Separate-Day Administration Group

    Children aged 12-23 months who are assessed as eligible for both vaccines on the same day, but whose guardians voluntarily choose to receive the varicella vaccine and the inactivated hepatitis A vaccine on different calendar days. Safety observation restarts for each administered vaccine, with an observation window of 30 days for the inactivated hepatitis A vaccine and 42 days for the live attenuated varicella vaccine, and active follow-up on Days 7, 30 and 42 after each vaccination. Completion of both vaccines, number of clinic visits, interval between doses, and reasons for delay are tracked through Day 90 after screening; parental satisfaction is assessed at Day 30. Children contribute to the overlapping exposure-based safety analysis sets according to the vaccine actually received at each visit, with the observation window restarting at each administration, so a child receiving both vaccines on separate days contributes to both sets.

    Biological: Live Attenuated Varicella Vaccine · Biological: Inactivated Hepatitis A Vaccine

  • Deferred/Unvaccinated Group

    Children aged 12-23 months who are assessed as eligible for vaccination on the day of screening, but whose guardians voluntarily choose to defer or not receive one or both of the study vaccines on that day (including temporary deferral for health reasons). This group does not contribute to post-vaccination safety analysis. It is followed only for acceptance-related and timeliness outcomes: completion of the two vaccines, number of clinic visits, and reasons for deferral or delay are tracked through Day 90 after screening. Guardians who decline study participation still receive routine vaccination services as usual.

Interventions

  • BiologicalLive Attenuated Varicella Vaccine

    Live attenuated varicella vaccine (Oka strain), given as a single 0.5 mL subcutaneous dose according to the national immunization schedule and the vaccine label. In this non-interventional study the vaccine is administered as routine care; the study does not assign, modify, or delay any vaccination. This is the exposure of interest for the 0-42 day safety observation window, including delayed varicella-like rash.

  • BiologicalInactivated Hepatitis A Vaccine

    Inactivated hepatitis A vaccine, given intramuscularly in the upper arm according to the national immunization schedule and the vaccine label. In this non-interventional study the vaccine is administered as routine care; the study does not assign, modify, or delay any vaccination. This is the exposure of interest for the 0-30 day safety observation window.

06

What researchers measure

Primary outcomes

  1. Acceptance rate of same-day co-administration

    Proportion of children eligible for both vaccines on the same day whose guardians choose same-day co-administration of the varicella vaccine and the inactivated hepatitis A vaccine. Denominator: children in the core analysis set (assessed eligible for both vaccines on the enrollment day). Reported as a percentage with 95% confidence interval.

    Time frame: Day 0 (at enrollment, i.e., the day of the vaccination decision)

  2. Completion rate of both vaccines within 90 days

    Proportion of children in the core analysis set who complete the study-relevant (due) doses of both the varicella vaccine and the inactivated hepatitis A vaccine within 90 days after screening. "Due doses" means the doses indicated at that visit and does not require completion of the full two-dose hepatitis A primary series within 90 days. Completion is verified through the immunization information system or guardians' vaccination records. Reported as a percentage with 95% confidence interval. This endpoint evaluates service delivery and short-term completion; the 90-day window is not a vaccine safety observation window.

    Time frame: Through 90 days after screening

Secondary outcomes

  1. Single-visit completion rate

    Proportion of children who complete all indicated study vaccines on the day of the first eligible visit. Denominator: children eligible for vaccination on that day. Reported as a percentage with 95% confidence interval.

    Time frame: Day 0

  2. Parental satisfaction score

    Guardian-reported satisfaction assessed with service-evaluation items covering clarity of pre-vaccination information, adequacy of explanation of the co-administration options, convenience of scheduling and on-site procedures, waiting time, staff communication and overall satisfaction, using 5-point Likert scales; the proportion willing to recommend the service to other parents is also reported. Analysis population: guardians of children in the core analysis set.

    Time frame: Day 30 (+/-5) after screening/enrollment visit (S0); for children vaccinated at later visits, the schedule and unified anchor are specified in the study operations manual

  3. Delayed or incomplete vaccination and number of clinic visits

    Proportion of children with delayed or incomplete vaccination beyond the recommended age window or within 90 days after screening, and the mean/median number of clinic visits required to complete both vaccines, compared between the post-implementation cohort and the historical control (pre-implementation) cohort using chi-square tests, rank-sum tests and multivariable adjustment or propensity score methods where appropriate.

    Time frame: Through 90 days after screening

  4. Incidence of solicited adverse events within 7 days after vaccination

    Incidence of solicited local reactions (pain/tenderness, erythema, swelling, induration, rash, itching) and systemic reactions (fever, acute allergic manifestations, diarrhea, nausea, vomiting, decreased appetite, abnormal crying, decreased activity) within 0-7 days after vaccination, collected by active follow-up on Day 7 (+/-2). Analyzed descriptively by vaccine exposure (same-day vs separate-day administration) with 95% confidence intervals.

    Time frame: 0-7 days after vaccination

  5. Incidence of adverse events within 30 days after hepatitis A vaccination

    Incidence of adverse events (AE) and serious adverse events (SAE) within 0-30 days after administration of the inactivated hepatitis A vaccine, including suspected adverse events following immunization (AEFI). Collected by 30-minute on-site observation, active follow-up on Days 7, 30 (+/-5) and 42 (+/-7), medical records review, and linkage to the national AEFI surveillance system. Analysis population: all doses of inactivated hepatitis A vaccine actually administered to study children, regardless of enrollment group (hepatitis A exposure analysis set); the observation window restarts at each administration, each dose contributes one 30-day observation, and the hepatitis A and varicella exposure sets overlap and are therefore not additive. Reported as percentages with 95% confidence intervals.

    Time frame: 0-30 days after hepatitis A vaccination

  6. Incidence of adverse events within 42 days after varicella vaccination

    Incidence of AE and SAE within 0-42 days after administration of the live attenuated varicella vaccine, with particular attention to delayed varicella-like rashes and fever, including AEFI. Collected by 30-minute on-site observation, active follow-up on Days 7, 30 (+/-5) and 42 (+/-7), medical records review, and linkage to the national AEFI surveillance system. Analysis population: all doses of live attenuated varicella vaccine actually administered to study children, regardless of enrollment group (varicella exposure analysis set); the observation window restarts at each administration, each dose contributes one 42-day observation, and the varicella and hepatitis A exposure sets overlap and are therefore not additive. Reported as percentages with 95% confidence intervals.

    Time frame: 0-42 days after varicella vaccination

07

Study locations

1 site
  • Juye County Center for Disease Control and Prevention
    Heze, Shandong 274900, China
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual participant data that underlie the results reported in this article will be made available, beginning 3 months and ending 5 years following article publication. Data will be shared with investigators whose proposed use of the data has been approved by an independent review committee. Proposals should be directed to the corresponding author.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Beginning 3 months and ending 5 years following the publication of the main study results.

Access criteria: Researchers who provide a methodologically sound proposal and have obtained approval from an independent review committee. Data will be shared upon execution of a data use agreement. Proposals should be directed to the corresponding author.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for May 2028, 18 months later.

Of 36 observational studies under Hepatitis, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 195. This study's planned 18 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2026
First posted
Nov 16, 2026
StartEst.
Nov 2026
Primary completionEst.
May 30, 2028
CompletionEst.
Jul 31, 2028
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07938151
Responsible party
Liping Yang (Associate Professor, Shandong University) — Principal investigator
First posted
Nov 16, 2026
Start date
Nov 2026 (estimated)
Primary completion
May 30, 2028 (estimated)
Completion
Jul 31, 2028 (estimated)
Last update
Nov 16, 2026

Study contacts

Mingyue Geng
Contact
gmy_cy@163.com
+86-19812542317
Liping Yang
principal investigator · Shandong University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion